A study of anti-SARS-CoV-2 antibody positivity in Duhok City, Iraq.

INTRODUCTION: The study aimed to investigate the positivity rate of anti-SARS-CoV-2 antibodies and associated factors. METHODOLOGY: Data and blood samples were collected between January 10th and December 30th, 2021 based on COVID-19 infection by using a designated questionnaire. The blood samples were used for the detection of total SARS-CoV-2 antibodies. RESULTS: 743 participants were recruited and 62.58% of them were positive for SARS-CoV-2 antibodies. Among these, 56.34% denied any symptoms of COVID-19. A higher positivity rate was found among females than men (OR = 1.5, CI = 1.1-2.0, p = 0.0073). Participants that had been diagnosed with COVID-19 in the past had a significantly higher prevalence of antibodies, and were nearly four times more likely to develop antibodies (OR = 4.0, CI = 2.4-6.8, p < 0.0001). Interestingly, only 3% of the participants with previous COVID-19 were seronegative while 46.54% were positive for antibodies without having a history of COVID-19 infection. Participants that reported symptoms were 2.6 times more likely to develop antibodies (OR = 2.6, CI = 1.9-3.6, p < 0.0001). Lastly, we found age to be significantly associated with the production of antibodies (CI = 13.3-14.7, p < 0.0001). CONCLUSIONS: The information from this study can be used to mitigate and develop tailored vaccination efforts and plan evidence-based strategies to better mitigate the ongoing COVID-19 pandemic in Kurdistan-Iraq.

Replacement Therapies in Metabolic Disease.

BACKGROUND: Replacement therapies have revolutionized treatment paradigms in metabolic diseases by restoring defective enzymes and supplementing missing downstream metabolites. Through most of the 20th century, no targeted therapies existed for these conditions, the only treatment options available focusing on symptoms rather than the underlying disorders. Improved understanding of the molecular pathways underlying metabolic disease has allowed not only supplementation of missing metabolites and reduction of upstream substrates, but replacement of defective or missing enzymes. OBJECTIVE: Modern genetic technologies have facilitated steady progress in recombinant enzyme innovation, providing treatments that replicate not only endogenous enzymes, but also their posttranslational modifications to optimize their delivery and function. The advent of the gene therapy revolution brings a possibility of new therapeutic opportunities in which the enzymes at the core of metabolic diseases may not only be added back, but genetically replaced. CONCLUSION: With the next generation of treatments approaching, this review examines the recent decades of replacement therapy innovation in metabolic disease and discusses the challenges and opportunities for the next generation of treatments.